Wall Street analyst estimates for DENTSPLY SIRONA Inc. (XRAY): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare.
Consensus price target
$12.50 (+17% vs price $10.65)
between $10.00 and $17.00 · 6 targets published in the last quarter
Closing price, Nov 4
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $3.6B | $3.5B – $3.6B | $1.53 | 10 |
| 2027E | $3.6B | $3.6B – $3.7B | $1.50 | 12 |
| 2028E | $3.7B | $3.7B – $3.8B | $1.64 | 9 |
Figures in USD · consensus as of October 15, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 12 |
| Hold | 19 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 32 |
| Avg rating (−2 sell to +2 buy) | 0.34 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $0.31 | ||
| 2026-08-06 | $0.52 | $0.35 | +49.4% |
| 2026-05-05 | $0.27 | $0.28 | -3.6% |
| 2026-02-26 | $0.27 | $0.28 | -3.6% |
| 2025-11-06 | $0.37 | $0.45 | -17.8% |
| 2025-08-07 | $0.52 | $0.50 | +4.0% |
| 2025-05-08 | $0.43 | $0.29 | +48.3% |
| 2025-02-27 | $0.26 | $0.47 | -44.7% |
Valuation Ratios
| Price / Book | 1.57 |
| Dividend Yield | 1.50% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.75B | $3.99B | $3.99B | $4.02B | $3.34B | $4.23B | $3.92B | $3.96B | $3.79B | $3.68B |
| Cost of Revenue | $1.74B | $1.80B | $1.92B | $1.86B | $1.68B | $1.88B | $1.79B | $1.88B | $1.83B | $1.84B |
| Gross Profit | $2.00B | $2.19B | $2.07B | $2.16B | $1.66B | $2.35B | $2.13B | $2.09B | $1.96B | $1.84B |
| Research & Development | $128.5M | $151.7M | $160.5M | $143.0M | $123.0M | $171.0M | $174.0M | $184.0M | $165.0M | $150.0M |
| Selling, General & Admin | $1.52B | $1.67B | $1.72B | $1.59B | $1.30B | $1.55B | $1.59B | $1.61B | $1.60B | $1.44B |
| Operating Expenses | $1.52B | $1.67B | $1.72B | $1.81B | $1.66B | $1.74B | $3.06B | $2.17B | $2.84B | $1.59B |
| Operating Income | $454.7M | -$1.59B | -$958.1M | $353.0M | -$3.0M | $608.0M | -$937.0M | -$85.0M | -$879.0M | $252.0M |
| EBITDA | $770.5M | -$1.25B | -$585.3M | $688.0M | $330.0M | $952.0M | -$662.0M | $249.0M | -$518.0M | -$46.0M |
| Interest Expense | $35.9M | $38.3M | $37.3M | $29.4M | $62.0M | $61.0M | $65.0M | $81.0M | $69.0M | $88.0M |
| Pre-tax Income | $440.9M | -$1.63B | -$958.4M | $338.0M | -$50.0M | $545.0M | -$1.05B | -$175.0M | -$936.0M | -$486.0M |
| Income Tax | $9.5M | -$53.2M | $52.5M | $82.0M | $23.0M | $134.0M | -$105.0M | -$43.0M | -$26.0M | $112.0M |
| Net Income | $429.9M | -$1.55B | -$1.01B | $256.0M | -$73.0M | $411.0M | -$950.0M | -$132.0M | -$910.0M | -$598.0M |
| EPS | $1.97 | -$6.86 | -$4.51 | $1.18 | -$0.38 | $1.88 | -$4.41 | -$0.62 | -$4.48 | -$3.00 |
| EPS (Diluted) | $1.94 | -$6.86 | -$4.51 | $1.17 | -$0.38 | $1.87 | -$4.41 | -$0.62 | -$4.48 | -$3.00 |
| Shares Outstanding (Diluted) | 221.6 M | 229.4 M | 224.3 M | 224.4 M | 219.2 M | 220.2 M | 215.5 M | 212.0 M | 203.2 M | 199.4 M |
Price
| Price | $10.65 (closing price, November 4, 2026) |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALGN · HSIC · NVST · ISRG · 0R29.L · BDX · 0R19.L · MDLN
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of XRAY: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks